Document is current
Any future updates will be listed below
-
Authors
Soochit, Widia
Sleutels, Frank http://orcid.org/0000-0001-6813-5209
Stik, Gregoire http://orcid.org/0000-0002-1404-1992
Bartkuhn, Marek
Basu, Sreya
Hernandez, Silvia C. http://orcid.org/0000-0002-6525-5296
Merzouk, Sarra
Vidal, Enrique http://orcid.org/0000-0002-4217-1807
Boers, Ruben http://orcid.org/0000-0002-3377-2897
Boers, Joachim
van der Reijden, Michael
Geverts, Bart
van Cappellen, Wiggert A. http://orcid.org/0000-0001-9059-8365
van den Hout, Mirjam http://orcid.org/0000-0003-2412-7631
Ozgur, Zeliha
van IJcken, Wilfred F. J. http://orcid.org/0000-0002-0421-8301
Gribnau, Joost
Renkawitz, Rainer
Graf, Thomas http://orcid.org/0000-0003-2774-4117
Houtsmuller, Adriaan
Grosveld, Frank http://orcid.org/0000-0002-7051-4715
Stadhouders, Ralph http://orcid.org/0000-0002-1060-5607
Galjart, Niels http://orcid.org/0000-0003-1964-3607
- License Information
-
More Information
Article History
Received: 2 July 2020
Accepted: 24 June 2021
First Online: 29 July 2021
Competing interests
: R.B., J.B., W.F.V.v.IJ. and J.G. report being shareholders in Methylomics B.V., a commercial company that applies MeD-seq to develop methylation markers for cancer staging. The other authors declare no conflicts of interest or financial interests.
